Chile's CFR makes $1.3bn bid for Adcock Ingram
This article was originally published in Scrip
A new pharma powerhouse centered in emerging markets is on the cards as Chilean firm CFR Pharmaceuticals has entered talks with South Africa's Adcock Ingram for a cash and shares deal valuing Adcock Ingram at $1.3bn. The combination of the two firms would create a company with combined revenues of about $1.3bn and particular strength in Latin America and sub-Saharan Africa.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.